Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S7681 and V769L
Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S7681 and V769L
复制标题
DOI：
10.1016/j.lungcan.2006.09.005
复制
发表时间：
2006-12-01
期刊：
影响因子：
5.3
通讯作者：
Nishimura, Masaharu
中科院分区：
文献类型：
--
作者：
Asahina, Hajime;Yamazaki, Koichi;Nishimura, Masaharu
表皮生长因子受体（EGFR）酪氨酸激酶（TK）结构域的突变与非小细胞肺癌（NSCLC）患者对EGFR-酪氨酸激酶抑制剂（EGFR-TKI）的临床反应性相关。然而，据报道，某些罕见的EGFR突变（包括S7681）对吉非替尼（一种EGFR-TKI）的体外敏感性低于主要突变（如外显子19缺失和L 858 R，甚至野生型突变）。在这里，我们报告了第一例肺腺癌，其中患者有罕见的突变S7681和V769 L，并与吉非替尼治疗。治疗6周期间疾病进展。这种情况表明，在体外敏感性吉非替尼与不同的临床反应吉非替尼在各种类型的EGFR突变。(C)2006爱思唯尔爱尔兰有限公司保留所有权利。
Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) are associated with clinical responsiveness to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell, lung cancers (NSCLCs). However, certain rare EGFR mutations including S7681 are reported to confer less in vitro sensitivity to gefitinib, an EGFR-TKI, than major mutations such as exon 19 deletions and L858R and even the wild-type counterpart. Here, we report the first case of adenocarcinoma of the lung in which the patient had rare mutations S7681 and V769L and was treated with gefitinib. Disease progressed during 6 weeks of treatment. This case suggests that in vitro sensitivity to gefitinib correlates with distinct clinical responsiveness to gefitinib in various types of EGFR mutations. (C) 2006 Elsevier Ireland Ltd. All rights reserved.